- $605.38m
- $422.26m
Climb Bio rises as FDA grants fast-track status to kidney disease drug
Brief: Climb Bio Announces FDA Fast Track Designation For Budoprutug For The Treatment Of Primary Membranous Nephropathy
Brief: Climb Bio Files Complaint Against Alumis And Acelyrin - SEC Filing
Brief: Climb Bio Appoints Susan Altschuller, Ph.D., MBA As Chief Financial Officer
Brief: Climb Bio Inc - Clym116 Phase 1 Trial Initiation Expected In Q4 2025
Brief: Climb Bio Reports First Quarter 2025 Financial Results
Brief: Climb Bio Files For Offering Of Common Stock Up To $22.4 Million - SEC Filing
Brief: Climb Bio Reports Fourth Quarter And Year-End 2024 Financial Results And Provides Business Updates
U.S. STOCKS ON THE MOVE-Astronics, Nike, Climb Bio
U.S. STOCKS ON THE MOVE-Astronics, Nike, Climb Bio
Climb Bio rises on antibody license deal with Beijing Mabworks
Brief: Climb Bio Signs Technology Transfer And License Agreement With Mabworks
Brief: Climb Bio To Be Added To The Nasdaq Biotechnology Index
Brief: Climb Bio Inc Files For Mixed Shelf Of Up To $200 Million - SEC Filing
Brief: Eliem Therapeutics Q2 operating expenses USD 56.372 million
Brief: Eliem Therapeutics Files Prospectus Relates To Resale From Time To Time Of Up To 36.8 Million Shares Of Common Stock By Selling Stockholders
Brief: Deep Track Capital LP Reports 5.85% Passive Stake In Eliem Therapeutics Inc As Of June 27 - SEC Filing
Brief: Eliem Therapeutics Announces The Closing Of Its Acquisition Of Tenet Medicines And Concurrent $120 Million Private Placement
Brief: Eliem Therapeutics Inc - Appointed Aoife Brennan As President And Chief Executive Officer Of Eliem